Evidence map›Paper›PMID 35589380›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2023

Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?

Julie Hias, Laura Hellemans, Karolien Walgraeve, Jos Tournoy, Christophe Vandenbriele, Lucas Van Aelst, Lorenz Roger Van der Linden

Open access · greenAbstract read
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Julie HiasHospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium.
Laura HellemansHospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium.ORCID 0000-0002-6787-9430
Karolien WalgraeveHospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium.
Jos TournoyDepartment of Geriatric Medicine, UZ Leuven, Leuven, Flemish Brabant, Belgium.
Christophe VandenbrieleDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Flemish Brabant, Belgium.
Lucas Van AelstDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Flemish Brabant, Belgium.
Lorenz Roger Van der LindenHospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium lorenz.vanderlinden@uzleuven.be.ORCID 0000-0001-5195-1891
Universitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients.

Indexed as

Heart FailurePatient DischargeAgedHeterocyclic Compounds, 2-RingHumansInpatientsPyrimidinesStroke VolumeHeterocyclic Compounds, 2-RingPyrimidinesvericiguatEVIDENCE-BASED MEDICINEGERIATRICSHeart failurePHARMACY SERVICE, HOSPITALPractice Guideline

Identifiers

PMID35589380
PMCPMC10647858
OpenAlexW4281252328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.